InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
September 08, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study
September 03, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020
August 25, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
August 10, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Second Quarter 2020 Financial Results
August 05, 2020 06:40 ET
|
InspireMD
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating...
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
July 23, 2020 08:00 ET
|
InspireMD
TEL AVIV, Israel, July 23, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...